29th Oct 2012 07:00
Cyprotex PLC
NOMAD Change of Name
29 October 2012 - Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces that is has novated its Nominated Adviser and Broker agreement with Singer Capital Markets Limited to Nplus1 Singer Advisory LLP ("N+1 Singer") with immediate effect. This follows the completion of the merger between Singer Capital Markets Limited and N+1 Brewin LLP.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) |
Tel: +44 (0) 20 3205 7500 |
Shaun Dobson Jenny Wyllie | www.nplus1singer.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Simon Conway Mo Noonan | www.fticonsulting.com
|
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Related Shares:
CRX.L